Study results further support the use of neoadjuvant immunotherapy in dMMR colon cancer

Three-year disease-free survival data from NICHE-2 and findings from NICHE-3 add to current knowledge on the benefits and provide further evidence for neoadjuvant immunotherapy in the treatment of mismatch repair-deficient (dMMR) colon cancer

https://dailyreporter.esmo.org/esmo-congress-2024/gastrointestinal-cancers/study-results-further-support-the-use-of-neoadjuvant-immunotherapy-in-dmmr-colon-cancer